Aredia Plaintiffs Slam Novartis Bid For Ex-Parte Talks

Law360, New York (December 7, 2007, 12:00 AM EST) -- Efforts by Novartis Pharmaceuticals Corp. to meet with treating physicians during the discovery phase of litigation over its bone cancer drugs have met with stiff opposition by the plaintiffs steering committee.

The committee filed an objection to the drug maker's motion for permission to engage in ex parte talks with the plaintiffs' doctors on Thursday in the U.S. District Court for the Middle District of Tennessee. The committee said Novartis did not offer facts to justify compelling a waiver of the plaintiffs' doctor-patient privileges.

Describing the...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.